HC Wainwright Lowers Earnings Estimates for Zymeworks

Zymeworks Inc. (NASDAQ:ZYME) – Equities researchers at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Zymeworks in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst R. Burns now anticipates that the company will earn $1.19 per share for the year, down from their prior forecast of $1.51. HC Wainwright currently has a “Buy” rating and a $56.00 price target on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.32 per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2026 earnings at $0.05 EPS, Q1 2027 earnings at $0.64 EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at $0.33 EPS, Q4 2027 earnings at ($0.78) EPS and FY2027 earnings at ($0.39) EPS.

Several other research firms also recently issued reports on ZYME. Wells Fargo & Company lifted their price target on Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. TD Cowen increased their price objective on shares of Zymeworks from $34.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday. B. Riley Financial reissued a “buy” rating and issued a $44.00 price objective (up from $40.00) on shares of Zymeworks in a research note on Monday, August 10th. Citizens Jmp restated a “market outperform” rating and set a $32.00 target price on shares of Zymeworks in a report on Wednesday, August 26th. Finally, Citigroup lifted their target price on shares of Zymeworks from $39.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Zymeworks presently has an average rating of “Moderate Buy” and an average price target of $42.67.

Zymeworks Stock Performance

ZYME opened at $29.07 on Thursday. The company has a market cap of $2.01 billion, a price-to-earnings ratio of 55.90 and a beta of 1.32. Zymeworks has a one year low of $18.20 and a one year high of $31.97. The business’s fifty day moving average is $27.48 and its two-hundred day moving average is $25.45.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings data on Monday, November 9th. The company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.27 by $0.01. The firm had revenue of $512.92 million during the quarter, compared to analysts’ expectations of $227.40 million. Zymeworks had a return on equity of 22.23% and a net margin of 16.10%. Zymeworks’s revenue was up 828.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.26) earnings per share.

Insider Activity

In other Zymeworks news, EVP Adam Schayowitz sold 13,832 shares of the business’s stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $25.85, for a total transaction of $357,557.20. Following the completion of the sale, the executive vice president owned 23,205 shares of the company’s stock, valued at approximately $599,849.25. The trade was a 37.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is owned by corporate insiders.

Institutional Trading of Zymeworks

Several large investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP raised its holdings in shares of Zymeworks by 21.7% during the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $175,280,000 after buying an additional 1,250,000 shares during the period. BlackRock Inc. purchased a new position in Zymeworks in the 2nd quarter worth approximately $111,122,000. Perceptive Advisors LLC grew its position in Zymeworks by 7.6% in the first quarter. Perceptive Advisors LLC now owns 3,510,078 shares of the company’s stock valued at $87,892,000 after acquiring an additional 248,228 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Zymeworks by 20.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,508,069 shares of the company’s stock valued at $39,949,000 after acquiring an additional 256,042 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Zymeworks by 6.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 743,898 shares of the company’s stock valued at $18,627,000 after purchasing an additional 43,896 shares during the period. 92.89% of the stock is currently owned by institutional investors and hedge funds.

More Zymeworks News

Here’s some of the latest news about ZYME:

• Positive Sentiment: Several analysts raised their price targets while maintaining Buy ratings. TD Cowen lifted its target to $39, Truist Financial raised its target to $36, and Citigroup increased its target to $44. HC Wainwright also raised its target to $56 and retained its Buy rating. TD Cowen price-target article Truist Financial article
• Positive Sentiment: Zymeworks reportedly reached a 52-week high after posting better-than-expected quarterly earnings, providing a positive signal about recent performance. Earnings and 52-week high article
• Negative Sentiment: HC Wainwright sharply reduced its earnings estimates for multiple quarters in 2026 and 2027. Its FY2027 forecast moved from earnings of $1.32 per share to a loss of $0.39, while its FY2026 estimate fell from $1.51 to $1.19. These cuts suggest a weaker expected earnings outlook and may be a near-term headwind, despite the firm keeping its Buy rating and $56 target.

Zymeworks Company Profile

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.